Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

CBDistillery CBD Vape Cartridge – Grand Daddy Purp GDP

Prices Are | Leafly Leafly Confusing? CBD Why Investigation: So



  • Prices Are | Leafly Leafly Confusing? CBD Why Investigation: So
  • Leafly Investigation: Why Are CBD Prices So Confusing?
  • Introduction
  • Some companies offer CBD at 5 cents per milligram. Others charge ten times as much. Joe Dolce clears up the pricing confusion. Honest review on CBD Capsules! Green Wellness Life CBD capsules provide the same benefits as CBD raw oil or tinctures, but without the. Summary. One year later the FDA repeated the test on 22 CBD products from other states: same result. But at this price, CBD is more of a luxury product than an.

    Prices Are | Leafly Leafly Confusing? CBD Why Investigation: So

    There are numerous ways to extract the resin, and some ways are safer than others. Certain preparations rely on chemicals like petroleum and butane for extraction; other methods involve using carbon dioxide. There may not be enough scientific research — yet — to prove without a doubt that CBD oil has medicinal and health benefits. Most of the studies that have been conducted on CBD have been done using CBD in pharmaceutical-grade preparations like oral solutions or pills.

    But many people report that CBD oils have helped them conquer everything from anxiety to pregnancy-related nausea to chronic pain. Since CBD does not produce as many adverse effects as THC, and helps mitigate those of THC, scientists are increasingly conducting more studies on the compound and its medical benefits.

    Does Marijuana Come in Pill Form? Most recently, the FDA approved Epidiolex , a drug that is prescribed to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, two rare and severe forms of epilepsy. The others go by these names: Each state has its own procedure for allowing its residents to purchase medical marijuana. These lists, while they vary from state to state, often include conditions like cancer, anxiety, and inflammatory bowel disease.

    Find a registered physician who will confirm in writing that you have a qualifying condition that would be improved by the drug. Receive an ID card that allows you to purchase medical marijuana at a dispensary. States, and sometimes counties within states, charge fees for card applications. Some, like California, will waive or reduce the fee for eligible patients. What Is a Dispensary? Dispensaries are the medical marijuana equivalent of pharmacies. They sell marijuana and other cannabis-derived products to people who have been certified by their home state to purchase it.

    Depending on what state you live in, you can also purchase marijuana for recreational use at dispensaries. Sign up for our Healthy Living Newsletter! Thanks for signing up for our newsletter! You should see it in your inbox very soon. Please enter a valid email address Subscribe We respect your privacy.

    National Academies of Sciences, Engineering, and Medicine. Novel Therapies for Arthritis? Journal of Pain and Symptom Management. Efficacy, Tolerability, and Safety of Cannabinoids in Gastroenterology: Among the many cannabinoids in the cannabis plant, cannabidiol CBD is a compound that does not produce the typical subjective effects of marijuana. The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry.

    A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties.

    In addition, basic and clinical investigations on the effects of CBD have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson.

    CBD is an useful and promising molecule that may help patients with a number of clinical conditions. Controlled clinical trials with different neuropsychiatric populations that are currently under investigation should bring important answers in the near future and support the translation of research findings to clinical settings.

    The plant Cannabis sativa cannabis contains more than chemical compounds that share a similar chemical structure, known as cannabinoids.

    Among the many cannabinoids in the plant, our group has focused on CBD, a compound that does not produce the typical subjective effects of marijuana 1. Since the s, our group has published a number of scientific articles showing the potential therapeutic effects of CBD in different animal models of neuropsychiatric disorders, as well as in clinical trials with humans. We were the first to demonstrate the anxiolytic and antipsychotic effects of CBD in animals, in the s and s, and later in humans, with rather promising results 2.

    In addition to anxiety and psychosis, basic and clinical research on other therapeutic possibilities of CBD was conducted. Moreover, patentable synthetic analogs of CBD with strong potential for knowledge transfer to the productive sector have recently been developed to offer the possibility of benefits for patients with many health conditions 3. The aim of the present review is to report the main contributions for the development of the therapeutical potential of CBD in neuropsychiatry, especially performed by Brazilian researchers, which helped to transform the view of CBD from an inactive cannabinoid to a medicine with multiple actions.

    Cannabidiol was isolated from cannabis extracts by Adams et al. However, no further investigation was carried out for almost 25 years, except for a few studies about its isolation. These findings opened a new research field on the pharmacological activity of cannabis constituents. In the early s, several studies reported that CBD was not able to mimic the effects of marijuana, which led to the belief that it would be a non-active cannabinoid.

    These studies indicated that CBD had pharmacological effects of its own, which have been investigated since then and led to the current view that CBD actually has a broad spectrum of action 2. In addition, these observations contributed to the understanding of the distinct effects of marijuana in different populations, explained by the varying concentrations of the plant's constituents.

    At the same time, the findings described here suggested that CBD could have anxiolytic and antipsychotic properties and gave rise to a line of research that continues to this day. After a boom in the s, the number of studies on CBD over the two decades that followed became stable, indicating a fall in the interest for the study of the therapeutic actions of this cannabinoid. Although a few groups continued to provide sparse contributions on the subject, much of the production in the field was limited to investigations of the anxiolytic, antidepressant, and antipsychotic properties of CBD performed by Brazilian researchers.

    As shown later, these properties have been confirmed in both laboratory animals and humans. Initial studies in this line yielded contradictory results. Whereas Zuardi and Karniol et al. Using this model and covering a full dose-response curve, they showed that in rats CBD does induce anxiolytic-like effects at lower doses 2.

    As discussed below, this bell-shaped dose-response curve was recently confirmed in humans tested in a clinical model of experimental anxiety. The EPM test is based on innate fear of open and elevated spaces and has been usually associated with general anxiety in humans.

    It was also found that CBD has a clear anti-stress effect after either acute or repeated administration, attenuating the behavioral and autonomic consequences of acute restraint stress 31 , 32 and the anxiogenic effects of chronic unpredictable stress [CUS— 28 ]. These effects could be associated with the antidepressant-like effects of CBD observed in the forced swimming stress, 33 , 34 , Wistar-Kyoto 35 and bulbectomy models CBD has a complex pharmacology, with several mechanisms proposed to explain its action.

    Most studies investigating CBD's mechanisms of action have been made in vitro 30 , but for more than 10 years now, in vivo studies using animal models has been investigating how CBD produces its beneficial effects in neuropsychiatric disorders.

    To discover the possible sites underlying CBD effects, a series of studies were performed in rodents using intracerebral drug administration into brain areas related to defensive responses, such as the medial prefrontal cortex mPFC , dorsal periaqueductal gray dPAG , bed nucleus of the stria terminallis BNST , amygdala, and hippocampus. CBD also modified anxiety-like behaviors in the mPFC, preventing the expression of contextual fear conditioning However, when CBD was tested in the EPM, the picture proved more complicated, as the drug produced opposite effects when injected into the prelimbic or infralimbic regions of the mPFC.

    In these regions the effects reported varied according not only to the animal model employed but also to previous stress experience 42 , Regarding the hippocampus, although the acute effect of CBD on this structure is still unknown, repeated administration of the drug prevented the anxiogenic effect of chronic stress by facilitating hippocampal neurogenesis The acute effects of CBD clearly depend on facilitation of serotonin 5HT1A receptor-mediated neurotransmission in defense-related areas 28 , 31 , 39 , 40 , 42 , 43 , 46 , Indeed, the acute effects of CBD in the marble burying test and aversive memory reconsolidation were prevented by CB1-receptor antagonists 24 , Facilitation of CB1- and CB2-mediated responses, probably due to inhibition of anandamide metabolism, is also involved in the pro-neurogenic effect of CBD According to comprehensive reviews, acute and chronic administration of CBD by various routes oral, inhaled, intravenous to healthy volunteers and patients with different clinical conditions did not induce significant adverse effects 50 , 51 , especially because a conversion of oral cannabidiol to THC seems not to occur in humans These results support previous observations from animal studies according to which CBD appears to be a safe compound for human use over a wide dose range.

    In this model, subjects are asked to speak for a few minutes in front of a video camera while the subjective state of anxiety and its physiological concomitants heart rate, blood pressure, skin conductance are recorded. The SPST was shown to be effective in inducing anxiety and sensitive to many anxiogenic and anxiolytic compounds.

    Through this test, the effects of CBD mg were compared with those produced by two anxiolytic compounds, ipsapirone 5 mg and diazepam 10 mg , in a double-blind, placebo-controlled procedure. The apparent validity of the SPST is intrinsic to social anxiety disorder SAD , since the fear of public speaking and its physiological companions are considered fundamental aspects of this anxiety disorder.

    Nonetheless, no studies had dealt with the anxiolytic effects of CBD in pathological anxiety until then. The group of SAD patients treated with CBD had lower anxiety levels in the performance and anticipatory phases of the test, lower negative self-assessment scores and fewer somatic symptoms compared with SAD patients who received placebo.

    More recently, we further confirmed and expanded this finding with subjects who were assigned to five groups that received CBD , , and mg , the benzodiazepine clonazepam 1 mg and placebo and underwent a test of public speaking in a real situation TPSRS where each volunteer had to speak in front of a group composed by the other participants.

    Again, the acute administration of CBD produced anxiolytic effects with a dose-dependent bell-shaped curve in healthy subjects, since the personal anxiety quantities were reduced with CBD mg, but not with the other CBD doses of and mg Therefore, these results highlight the need to establish the accurate therapeutic dose ranges of CBD for each clinical condition.

    Brain sites associated with the anxiolytic effects of CBD. The first neuroimaging study conducted to investigate the central effects of CBD in humans used single-photon emission computed tomography SPECT to evaluate healthy volunteers who received CBD mg or placebo in two laboratory sessions, 1 week apart, in a crossover, double-blind procedure The whole procedure induced anxiety 58 , allowing the investigation of potential anxiolytic effects of CBD.

    This brain activity pattern associated with the use of CBD was regarded as compatible with a central anxiolytic effect in these areas. Focus of significantly increased yellow and decreased blue rCBF in the left hippocampal area in healthy subjects A 57 and subjects with social anxiety disorder SAD; B 59 following the administration of CBD vs.

    In a series of neuroimaging studies, functional magnetic resonance imaging fMRI was used to investigate the neural correlates of the anxiolytic effects of CBD in 15 healthy subjects This method allowed the acquisition of larger number of images with better spatial and temporalresolution. CBD mg modulated the patterns of brain activity while subjects processed stimuli depicting intensely fearful faces, attenuating responses in the anterior and posterior cingulate and amygdala.

    Moreover, this finding had a direct correlation with the concomitant effect of CBD in the modulation of skin conductance responses to fearful stimuli. In a subsequent study, it was also demonstrated that CBD produces its anxiolytic effects by altering prefrontal-subcortical connectivity via amygdala and the anterior cingulate More recently, we performed the first study to examine the neural correlates of the anxiolytic effects of CBD in a clinical sample 59 , using the same protocol, design and dose mg as in the SPECT study with healthy volunteers described above We found that, when compared to placebo, CBD was able to reduce subjective measures of anxiety without inducing sedation in treatment-naive SAD patients.

    Together, these results show that the modulatory effects of CBD in limbic and paralimbic areas are compatible with the effects of anxiolytic compounds on healthy subjects and in patients with anxiety disorders 62 — Using classical animal models to evaluate antipsychotic effects, Zuardi et al. As opposed to the latter, however, CBD did not induce catalepsy, a motor impairment associated with antipsychotic extrapyramidal side effects in humans. These effects were similar to those of clozapine, suggesting that CBD could have an atypical antipsychotic profile The investigations were expanded to glutamatergic-based animal models of schizophrenia, which showed that CBD decreased hyperlocomotion and PPI impairment caused by the glutamate NMDA receptor non-competitive antagonists ketamine and MK, respectively 67 , In the former study, CBD was administered chronically for 21 days and was also able to decrease the social impairment and memory deficits induced by the repeated administration of MK Again, these effects were similar to those of the antipsychotic clozapine.

    Interestingly, in promising a recent study we found that peripubertal treatment with CBD inhibited the development of hyperlocomotion induced by prenatal treatment with poly I: C, indicating that this cannabinoid may have long-lasting properties of a peripubertal treatment as an intervention to prevent psychosis exhibited in the adulthood The translations of these findings to ultra-high-risk subjects to psychosis and in individuals in the early prodromal phases of schizophrenia of great importance, thus studies in this area are underway.

    CBD did not induce catalepsy in any of the investigations available to date. In fact, CBD prevented and partially reversed catalepsy caused by haloperidol As discussed below, this result is consonant with the clinical finding that CBD, in addition to blocking L-DOPA-induced psychotic symptoms, may also improve motor impairment in Parkinson's patients In an early work, we observed that CBD produced a pattern of neuronal activation measured by the expression of the proto-oncogene cFos similar to that of clozapine, but distinct from haloperidol.

    Whereas the three drugs increased activation in limbic areas, only CBD and clozapine increased activation in the mPFC. Haloperidol, on the other hand, induced a significant increase in cFos expression in the striatum Confirming the involvement of limbic sites in its antipsychotic effects, CBD blocked PPI impairment induced by amphetamine after direct injection into the nucleus accumbens This result suggests that the anti-inflammatory action of CBD see 30 , for a review , could be related to its antipsychotic properties and is consonant with recent findings that anti-inflammatory drugs such as minocycline could be useful in the treatment of schizophrenia In , Zuardi and colleagues published the first case report of a schizophrenia patient treated with CBD The fact that, from the two schizophrenia patients who did not respond, one reduced psychotic symptoms only with clozapine and the other was resistant even to this drug, may justify the findings.

    None of the patients presented side effects while in treatment with CBD, as previously observed in schizophrenic patients who received CBD and were assessed with electrodermal responsiveness to auditive stimuli and the Stroop Color Word Test Later, three double blind, controlled clinical trials that investigated the efficacy and tolerability of CBD in schizophrenia patients confirmed our preliminary findings.

    Both treatments significantly reduced psychotic symptoms, with no differences between them; however, CBD induced fewer side effects compared to amisulpride. The antipsychotic effects of CBD were also investigated in first-episode schizophrenia patients treated for 14 days in a crossover, placebo-controlled trial CBD significantly decreased psychotic symptoms after 2 weeks when compared to baseline, although the differences from placebo failed to reach statistical significance.

    After the treatment, the CBD group presented lower positive psychotic scores and improved cognitive and general illness symptoms. CBD and placebo side-effects were equivalents between groups.

    Since the antipsychotic effects of CBD do not appear to depend on dopamine receptor antagonism, this compound may indeed represent a new class of treatment for the psychotic disorders in general and schizophrenia, in particular.

    The view that CBD could have antipsychotic effects was further supported by our studies in healthy human subjects with artificially induced psychosis 80 , In a double blind, placebo-controlled trial, CBD mg was shown to attenuate depersonalization symptoms induced by the N-methyl-D-aspartate NMDA receptor antagonist ketamine, which increases glutamate release at low doses This effect on dissociative symptoms also raised hypotheses of potential therapeutic uses of CBD in conditions such as post-traumatic stress disorder PTSD , intoxication by cannabis, and some personality disorders.

    The management of frequent psychotic symptoms in patients with Parkinson's disease PD is regarded as a major challenge for clinicians.

    It is particularly concerning because i the reduction of the doses of antiparkinsonian medications or the addition of conventional antipsychotics worsens motor function; and ii atypical antipsychotics may have significant side effects especially in the neurological and hematological domains Thus, considering the pertinence of a possible antipsychotic effect of CBD and the lack of effective and safe pharmaceutical management for psychosis in PD, we evaluated the efficacy and safety of this cannabinoid in patients with PD who had psychotic symptoms Interestingly, we observed a reduction of both psychotic and motor symptoms during CBD treatment, with no worsening on cognition.

    These preliminary results suggested that CBD could have potential beneficial effects in PD, which led us to investigate this possibility in greater depth see below. In a series of collaborative fMRI studies, the effects of CBD were investigated on behavior and regional brain activity in several areas, providing initial clues about its mechanisms and sites of action. It was thus possible to hypothesize that the opposing effects of these two cannabinoids on brain modulation could be related both to their antagonism but also to the intrinsic antipsychotic effect of CBD.

    The cloning and description of the CB1 and CB2 cannabinoid receptors in the central system and the subsequent isolation of the endocannabinoids in the early s renewed the interest in the investigation of cannabinoid compounds 2. As a result, there has been a constant increase in the number of investigations on CBD since then, stimulated mainly by discoveries of new therapeutical possibilities of the drug.

    Although the endocannabinoid system has aroused a promising target in the field of neuroprotection, no trials to date have assessed neuroprotective treatments with CBD for PD. Thus, following an open-trial evaluating the antipsychotic effects of CBD in PD with psychotic features, we tested this cannabinoid in PD patients with no psychiatric comorbidities or dementia Our findings suggest that CBD may be able to improve general parkinsonism in PD patients with no psychiatric comorbidities.

    However, we found that CBD seems to have antioxidant and neuroprotective properties, as it increased the levels of brain-derived neurotrophic factor 89 , In addition, CBD increased mitochondrial complex and creatine kinase activity 91 , reversed oxidative stress parameters TBARS formation and protein carbonyls 92 , and prevented cognitive impairments 92 , In another study, acute and chronic CBD administration More recently, we found that CBD reversed iron-induced effects, normalizing hippocampal DNM1L, synaptophysin, and caspase 3 levels in rats and once again suggesting that CBD should be considered as a compound with neuroprotective and memory-rescuing properties Our brain continually changes in the course of our lifetime, and the investigation of mechanism involving neuroplasticity offers a great opportunity for the study of maladaptive mechanisms that lead to mental illness and possible new targets for their treatment Neuropsychiatric disorders might be a result of profound changes in mechanism related to brain functions probably involving neuroplasticity For instance, reduced hippocampal volume is observed in patients diagnosed with mood disorders, post-traumatic stress disorder PTSD , schizophrenia and Alzheimer's Disease In rodents, exposure to protocol of chronic stressors, that modeling some features of psychiatric disorders symptoms, induce alterations in dendritic remodeling and decrease adult hippocampal neurogenesis 38 , 44 , Adult hippocampal neurogenesis is complex multi-step process that covers division, survival not all neurons that divide will survive , migration and differentiation of new cells in the dentate gyrus of the hippocampus , In the hippocampus, this process is thought to be determinant in at least some forms of learning and memory.

    Disturbed adult hippocampal neurogenesis has been recognized as one of the central mechanisms related to the reduction of hippocampal volume reported in patients suffering from mood disorders and schizophrenia.

    Lower rates of hippocampal neurogenesis were found in post-mortem tissues of schizophrenia patients and depressive patients , Derivatives of Cannabis sp have been investigated for their potential effects on neuroplasticity. In , Jiang and co-workers observed that the chronic treatment with a synthetic cannabinoid HU enhanced neurogenesis in rats. Regarding CBD, Wolf et al. Results from our group suggested that in chronically stressed mice, CBD prevents stress-induced decreased hippocampal neurogenesis and stress-induced anxiogenesis.

    These results indicated that the behavioral effect of CBD in stressed mice was partially dependent on the integrity of the neurogenic capacity of the hippocampus. Recently, Schiavon et al. Interesting, Demirakca et al. Critical revision of the manuscript for important intellectual content: Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and declare support from the Swiss Federal Office of Public Health FOPH for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work.

    No additional disclosures were reported. The FOPH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The decision to submit the article for publication was a condition of the funding and was made before any results were available.

    Dr Whiting drafted the article, produced tables and figures and performed the analysis. Mr Duffy and Ms Misso conducted the literature searches. Drs Whiting, Wolff, and Lang screened searched results and selected full-text studies for inclusion. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Neither of these individuals received additional compensation in association with their work on this article.

    This article was corrected online June 26, , for incorrect axis labeling in Figure 4; on July 13, , for a corrected average reduction to the Ashworth spasticity scale as reported in the Abstract ; on November 5, , for an incorrect nonproprietary name and approved use for a drug in Table 1; and on April 12, , for an incorrect effect estimate. Flow of Studies Through the Review Process. Search Strategy eAppendix 3.

    Nausea and Vomiting Due to Chemotherapy eAppendix 4. Chronic Pain eAppendix 6. Spasticity in MS and Paraplegia eAppendix 7. Anziety Disorder eAppendix 9. Sleep Disorder eAppendix Tourette Syndrome eAppendix A practical and natural taxonomy for cannabis. SY global epidemiology of cannabis use and implications for public health. Single Convention on Narcotic Drugs, The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms.

    PubMed Google Scholar Crossref. The prevalence and incidence of medicinal cannabis on prescription in the Netherlands. Eur J Clin Pharmacol. Office of National Drug Control Policy. State Laws Related to Marijuana. Accessed May 18, Cochrane Handbook for Systematic Reviews of Interventions.

    The Cochrane Collaboration website. Accessed March 23, Centre for Reviews and Dissemination. University of York; Canadian Agency for Drugs and Technologies in Health. Accessed March 17, Interrater reliability of a modified Ashworth scale of muscle spasticity. Meta-analysis in clinical trials. Quantifying heterogeneity in a meta-analysis.

    Proc Am Assoc Cancer Res. A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine. Proc Am Soc Clin Oncol. Randomized placebo controlled trial of dronabinol in obstructive sleep apnea. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. Accessed April 7, Center for Medicinal Cannabis Research.

    Efficacy of inhaled cannabis in diabetic painful peripheral neuropathy. A clinical trial on the antipsychotic properties of cannabidiol. A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy.

    EU Clinical Trials Register. Accessed August 4, A study to evaluate the effects of cannabis based medicine in patients with pain of neurological origin. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.

    J Pain Symptom Manage. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.

    Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.

    A randomised multicentre single blind comparison of a cannabinoid anti-emetic levonantradol with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting.

    Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy. A double-blind, controlled trial of nabilone vs. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. Antiemetic effect of tetrahydrocannabinol: Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.

    Antiemetics in patients receiving chemotherapy for cancer: N Engl J Med. Deltatetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Cannabis and cancer chemotherapy: Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea.

    Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children.

    Dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting. Comparison of deltatetrahydrocannabinol THC , prochlorperazine PCP and placebo as anti-emetics for cancer-chemotherapy.

    Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting CINV. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting.

    Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Short-term effects of cannabinoids in patients with HIV-1 infection: The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome: Effect of dronabinol on nutritional status in HIV infection.

    Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. The effects of nabilone on sleep in fibromyalgia: Low-dose vaporized cannabis significantly improves neuropathic pain. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: Smoked cannabis for chronic neuropathic pain: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product Sativex in painful diabetic neuropathy: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

    Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. Nabilone for the treatment of pain in fibromyalgia. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Sativex successfully treats neuropathic pain characterised by allodynia: Cannabis in painful HIV-associated sensory neuropathy: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis.

    Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Analgesic effect of deltatetrahydrocannabinol. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

    Effect of smoked cannabis on painful diabetic peripheral neuropathy. Sativex in the treatment of central neuropathic pain due to spinal cord injury: The effects of nabilone on insomnia in fibromyalgia: McGill University Health Center. Nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia.

    Sativex versus placebo when added to existing treatment for central neuropathic pain in MS. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Benefit of an add-on-treatment with a synthetic cannabinomimeticum on patients with chronic back pain-a randomized controlled trial.

    Paper presented at 8th International Conference on Early Psychosis: A multi-centre, double-blind, randomized, controlled trial of oro-mucosal cannabis based medicine in the treatment of neuropathic pain characterized by allodynia. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: Randomised controlled trial of cannabis based medicinal extracts CBME in central neuropathic pain due to multiple sclerosis.

    Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Effects of smoked marijuana on neuropathic pain. Medicinal cannabis for painful HIV neuropathy. University of California Davis. Effects of vaporized marijuana on neuropathic pain.

    Leafly Investigation: Why Are CBD Prices So Confusing?

    The legal status of CBD in the USA is extra complicated, because many . In this study, 46 different cannabis oil samples were collected directly from although a fuller review on the risks and benefits of CBD is still being planned. .. Site Licenses · Pricing · Downloads · Rights & Permissions · Help. A partial summary of a page internal report is provided herein. .. (18) Dolce , J. Leafly Investigation: Why Are CBD Prices So Confusing?. So far, CBD is the most promising compound from both a marketing and are reading and supporting our independent, investigative reporting.




    The legal status of CBD in the USA is extra complicated, because many . In this study, 46 different cannabis oil samples were collected directly from although a fuller review on the risks and benefits of CBD is still being planned. .. Site Licenses · Pricing · Downloads · Rights & Permissions · Help.


    A partial summary of a page internal report is provided herein. .. (18) Dolce , J. Leafly Investigation: Why Are CBD Prices So Confusing?.


    So far, CBD is the most promising compound from both a marketing and are reading and supporting our independent, investigative reporting.


    Currently, cannabis is legal for medical purposes in 50% of the states, and another Controlled clinical trials are underway to investigate the use of CBD as a . distribution/retail sales, to purchase and possession by the ultimate patient users. . have to be conducted under an IND and approved by an Institutional Review.


    CL also tested hempseed oils as part of its review of seed oil supplements as sources Two conditions for which CBD has been or is being investigated as a new drug are . The trouble is that it costs $80 for only 44 grams (!.


    Does the FDA object to the clinical investigation of marijuana for medical use? Can products that contain THC or cannabidiol (CBD) be sold as dietary is to review data submitted to the FDA in an application for approval to.

    Add Comment